Applications of Genomics in Melanoma Oncogene Discovery

被引:26
作者
Berger, Michael F. [2 ]
Garraway, Levi A. [1 ,2 ,3 ]
机构
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[2] Broad Inst MIT & Harvard, Cambridge Ctr 7, Cambridge, MA 02142 USA
[3] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA
关键词
Melanoma; Oncogene; DNA sequencing; Microarrays; Gene amplification; Targeted therapy; CUTANEOUS MALIGNANT-MELANOMA; BLADDER-CARCINOMA ONCOGENE; N-RAS MUTATIONS; HUMAN CANCER; IMATINIB MESYLATE; METASTATIC MELANOMA; TRANSFORMING GENES; BRAF MUTATIONS; LUNG-CANCER; COPY NUMBER;
D O I
10.1016/j.hoc.2009.03.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The identification of recurrent alterations in the melanoma genome has provided key insights into the biology of melanoma genesis and progression. These discoveries have come about as a result of the systematic deployment and integration of diverse genomic technologies, including DNA sequencing, chromosomal copy number analysis, and gene expression profiling. Here, the discoveries of several key melanoma oncogenes affecting critical cell pathways are described and the role played by evolving genomics technologies in melanoma oncogene discovery is examined. These advances are being exploited to improve prognosis and treatment of melanoma patients through the development of genome-based diagnostic and targeted therapeutic avenues.
引用
收藏
页码:397 / +
页数:19
相关论文
共 50 条
[21]   Genomics in target and drug discovery [J].
van Duin, M ;
Woolson, H ;
Mallinson, D ;
Black, D .
BIOCHEMICAL SOCIETY TRANSACTIONS, 2003, 31 :429-432
[22]   Oncogene-directed small molecule inhibitors for the treatment of cutaneous melanoma [J].
Eliades, Philip ;
Flaherty, Keith T. ;
Tsao, Hensin .
MELANOMA MANAGEMENT, 2015, 2 (02) :133-147
[23]   Oncogene-induced senescence and melanoma: where do we stand? [J].
Peeper, Daniel S. .
PIGMENT CELL & MELANOMA RESEARCH, 2011, 24 (06) :1107-1111
[24]   Meta-Analysis and Systematic Review of the Genomics of Mucosal Melanoma [J].
Broit, Natasa ;
Johansson, Peter A. ;
Rodgers, Chloe B. ;
Walpole, Sebastian T. ;
Newell, Felicity ;
Hayward, Nicholas K. ;
Pritchard, Antonia L. .
MOLECULAR CANCER RESEARCH, 2021, 19 (06) :991-1004
[25]   Advances in the discovery and development of melanoma drug therapies [J].
Chanda, Monica ;
Cohen, Mark S. .
EXPERT OPINION ON DRUG DISCOVERY, 2021, 16 (11) :1319-1347
[26]   Impact of genomics on the surgical management of melanoma [J].
Ferguson, P. M. ;
Long, G. V. ;
Scolyer, R. A. ;
Thompson, J. F. .
BRITISH JOURNAL OF SURGERY, 2018, 105 (02) :E31-E47
[27]   Epha2 is a critical oncogene in melanoma [J].
D Udayakumar ;
G Zhang ;
Z Ji ;
C-N Njauw ;
P Mroz ;
H Tsao .
Oncogene, 2011, 30 :4921-4929
[28]   Gold nanostructures in melanoma: Advances in treatment, diagnosis, and theranostic applications [J].
Dastgheib, Zahra Sadat ;
Abolmaali, Samira Sadat ;
Farahavar, Ghazal ;
Salmanpour, Mohsen ;
Tamaddon, Ali Mohammad .
HELIYON, 2024, 10 (15)
[29]   DEK oncogene is overexpressed during melanoma progression [J].
Riveiro-Falkenbach, Erica ;
Ruano, Yolanda ;
Garcia-Martin, Rosa M. ;
Lora, David ;
Cifdaloz, Metehan ;
Acquadro, Francesco ;
Ballestin, Claudio ;
Ortiz-Romero, Pablo L. ;
Soengas, Maria S. ;
Rodriguez-Peralto, Jose L. .
PIGMENT CELL & MELANOMA RESEARCH, 2017, 30 (02) :194-202
[30]   Transcriptional control analyses of the Xiphophorus melanoma oncogene [J].
Regneri, Janine ;
Volff, Jean-Nicolas ;
Schartl, Manfred .
COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-TOXICOLOGY & PHARMACOLOGY, 2015, 178 :116-127